New England Journal of Medicine · 2025 · 117 citations · 19 references
MedicineCell BiologyEndocrinologyCell TherapyDiabetologyStem Cell TransplantationAllogeneic Stem Cell TransplantationDiabetes ManagementDiabetes MellitusGlycemic ControlHypoglycemia ManagementPancreas TransplantationAllogeneic Stem Cell InfusionAllogeneic Stem Cell TherapyGlycated Hemoglobin MonitoringPancreatic Islet Cell TransplantationPancreatic Islet EngraftmentPancreatic Islet FunctionStem Cell-derived Beta CellsStem Cell-derived Endocrine Cells
BACKGROUND: Zimislecel is an allogeneic stem cell-derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. METHODS: cells) as a single infusion. All the participants also received glucocorticoid-free immunosuppressive therapy. The primary end point in part A was safety. The primary end point in part C was freedom from severe hypoglycemic events during days 90 through 365, with a glycated hemoglobin level of less than 7% or a decrease of at least 1 percentage point from baseline in the glycated hemoglobin level at one or more time points between days 180 and 365. Secondary end points in part C included safety and insulin independence between days 180 and 365. Assessment of the primary and secondary end points in part C involved the participants who received the full dose of zimislecel as a single infusion in part B or C. Detection of serum C-peptide during a 4-hour mixed-meal tolerance test was used to assess engraftment and islet function. All the analyses were interim and not prespecified. RESULTS: A total of 14 participants (2 in part A and 12 in parts B and C) completed at least 12 months of follow-up and were included in the analyses. C-peptide was undetectable at baseline in all 14 participants. After zimislecel infusion, all the participants had engraftment and islet function, as evidenced by the detection of C-peptide. Neutropenia was the most common serious adverse event, occurring in 3 participants. Two deaths occurred - one caused by cryptococcal meningitis and one by severe dementia with agitation owing to the progression of preexisting neurocognitive impairment. All 12 participants in parts B and C were free of severe hypoglycemic events and had a glycated hemoglobin level of less than 7%; these participants spent more than 70% of the time in the target glucose range (70 to 180 mg per deciliter). Ten of the 12 participants (83%) had insulin independence and were not using exogenous insulin at day 365. CONCLUSIONS: The results of this small, short-term study involving persons with type 1 diabetes support the hypothesis that zimislecel can restore physiologic islet function, warranting further clinical investigation. (Funded by Vertex Pharmaceuticals; VX-880-101 FORWARD ClinicalTrials.gov number, NCT04786262.).
19
Generation of Functional Human Pancreatic β Cells In Vitro
Felicia W. Pagliuca, Jeffrey R. Millman, Mads Gürtler et al. · Cell · 2014 · 2K citations · Full text
Gabriel A Gregory, Thomas I. G. Robinson, Sarah E Linklater et al. · The Lancet Diabetes & Endocrinology · 2022 · 1.1K citations
Public Health, Chronic Disease Prevention, Population Health Sciences +13
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Jane L. Chiang, M. Sue Kirkman, Lori M. Laffel et al. · Diabetes Care · 2014 · 969 citations · Full text
Medicine, Endocrinology, Immunology +15